Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China

BACKGROUND: Our objective is to compare the cost-utility of icotinib and gefitinib for the second-line treatment of advanced non-small cell lung cancer (NSCLC) from the perspective of the Chinese healthcare system. METHODS: Model technology was applied to assess the data of randomized clinical trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chunxiang, Zhang, Hongmei, Shi, Jinning, Wang, Dong, Zhang, Xiuwei, Yang, Jian, Zhai, Qizhi, Ma, Aixia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4807816/
https://www.ncbi.nlm.nih.gov/pubmed/27015267
http://dx.doi.org/10.1371/journal.pone.0151846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4807816/
https://www.ncbi.nlm.nih.gov/pubmed/27015267
http://dx.doi.org/10.1371/journal.pone.0151846

Ejemplares similares